Mode
Text Size
Log in / Sign up
Phase 3 Completed N=353 Randomized Double-blind Treatment

Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus

Source: ClinicalTrials.gov NCT00086502 ↗
Enrolled (actual)
353
Serious AEs
3.7%
Results posted
Apr 2010
Primary outcomePrimary: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 — -0.85; -0.15 Percent — p=<0.001

Summary

The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24
-0.85; -0.15 <0.001 sig
SECONDARY
Change From Baseline in FPG (Fasting Plasma Glucose) at Week 24
-16.7; 1.0 <0.001 sig

Eligibility Criteria

Inclusion Criteria

  • Patient has type 2 diabetes mellitus (T2DM)
  • Patient is 18 years of age (or older)
  • Patient is not pregnant or breast-feeding and does not plan to become pregnant for the duration of the study and poststudy follow-up period

Exclusion Criteria

  • Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis
  • Patient required insulin within the prior 8 weeks
  • Patient is on a weight loss program and is not in the maintenance phase
  • Patient started on a weight loss medication (e.g., orlistat or sibutramine) within the prior 8 weeks
  • Patient is on or likely to require treatment with treatment with immunosuppressive agents (e.g., cyclosporin, methotrexate)
  • Patient has cirrhosis, active liver disease (other than fatty liver) or symptomatic gallbladder disease
  • Patient has chronic myopathy, or a progressive neurological or neuromuscular disorder (e.g., multiple sclerosis or polymyositis)
  • Patient has any of the following disorders within the past 6 months:

Acute coronary syndrome (e.g., MI or unstable angina), Coronary artery intervention, Stroke or transient ischemic neurological disorder.

  • Patient has new or worsening signs or symptoms of coronary heart disease within the past 3 months
  • Patient has severe peripheral vascular disease
  • Patient has congestive heart failure
  • Patient is HIV positive
  • Patient has a clinically important hematological disorder (e.g., aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)
  • Patient has a history of neoplastic disease
  • Patient has a history of alcohol or drug abuse within the past 3 years
  • Patient has viral hepatitis (hepatitis B or C)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00086502). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search